The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 382 participants.

Also called NCT03288038

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 382 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03288038
Other papers using this trial's data
  • Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia Clinical therapeutics, 2018-06 DOI, PubMed 29857919

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03288038. Randomized; double masking; primary purpose treatment. Start 2014-10-13 (actual); primary completion 2015-11-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia
Condition
Hypercholesterolemia
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Ezetimibe
Lead sponsor
Shin Poong Pharmaceutical Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03288038
Content hash
c6054039706bf3d5ff2f5cac64d056292ac4aadaf145a14d74233b752e6a0ce0